Clinical Trial: A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880536) titled 'A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors' on March 11.

Brief Summary: The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.

Study Start Date: March 14

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: BIOLOGICAL: mRNA-4106

Intramuscular Injection

BIOLOGICAL: Nivolumab/Relatlimab

Intravenous infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ModernaTX, Inc.

Published by HT...